These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 30663563)
1. Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer. Ruan WC; Che YP; Ding L; Li HF Comb Chem High Throughput Screen; 2018; 21(10):718-724. PubMed ID: 30663563 [TBL] [Abstract][Full Text] [Related]
2. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis. Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials. You XH; Jiang YH; Fang Z; Sun F; Li Y; Wang W; Xia ZJ; Wang XZ; Ying HQ ESMO Open; 2020 Mar; 4(Suppl 2):. PubMed ID: 32132090 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Baraniskin A; Buchberger B; Pox C; Graeven U; Holch JW; Schmiegel W; Heinemann V Eur J Cancer; 2019 Jan; 106():37-44. PubMed ID: 30476731 [TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis. Hu W; Xu WS; Liao XF; He HJ Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763 [TBL] [Abstract][Full Text] [Related]
7. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials. Wu YS; Shui L; Shen D; Chen X Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044 [TBL] [Abstract][Full Text] [Related]
8. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis. Wang M; Zheng X; Ruan X; Ye B; Cai L; Lin F; Tu J; Jiang F; Li S Chin Med J (Engl); 2014; 127(3):538-46. PubMed ID: 24451964 [TBL] [Abstract][Full Text] [Related]
10. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis. Li Z; Huang Y; Zhao R; Cui Y; Zhou Y; Wu X Sci Rep; 2018 Jan; 8(1):510. PubMed ID: 29323221 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis. Zhou M; Yu P; Qu J; Chen Y; Zhou Y; Fu L; Zhang J Cell Physiol Biochem; 2016; 40(1-2):361-369. PubMed ID: 27866194 [TBL] [Abstract][Full Text] [Related]
13. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258 [TBL] [Abstract][Full Text] [Related]
14. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis. Cao D; Zheng Y; Xu H; Ge W; Xu X Sci Rep; 2019 Dec; 9(1):20326. PubMed ID: 31889159 [TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials. Liang RF; Zheng LL Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630 [TBL] [Abstract][Full Text] [Related]
16. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis. Kaveh S; Ebrahimi P; Rezapour A; Mozafari M; Sayehmiri K Int J Clin Pharm; 2019 Feb; 41(1):30-41. PubMed ID: 30610548 [TBL] [Abstract][Full Text] [Related]
18. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis. Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741 [TBL] [Abstract][Full Text] [Related]
19. Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings. Houts AC; Ogale S; Zafar Y; Hubbard JM; Satram-Hoang S; Sommer N; Walker MS J Gastrointest Cancer; 2019 Mar; 50(1):16-22. PubMed ID: 29058260 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date. Zhang G; Zhou X; Lin C Int J Clin Exp Med; 2015; 8(1):1434-45. PubMed ID: 25785152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]